Metamizol Meditop (Metamizole Sodium Monohydrate)

Metamizole Sodium works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces inflammation. It also acts on central nervous system pathways to provide analgesia and influences the hypothalamic set‑point to produce antipyretic effects.

The specific dose of Metamizol Meditop is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of Metamizole Sodium in pregnancy or lactation has not been definitively established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole belongs to the pyrazolone class, offering potent analgesic and antipyretic effects with a rapid onset. Compared with traditional NSAIDs, it may have a lower risk of gastrointestinal irritation but carries a rare risk of severe blood disorders, requiring regular monitoring.

Metamizol Meditop should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability and potency.

Metamizol Meditop is administered orally. The tablet or liquid is taken by mouth with or without food, according to the prescribing physician’s instructions. Swallow the medication whole unless directed otherwise.

The most serious risks include agranulocytosis, aplastic anemia, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for signs of infection, unusual bleeding, rash, or breathing difficulties, and seek immediate medical attention if they occur.

Metamizol Meditop should be avoided in individuals with known hypersensitivity to Metamizole Sodium or other pyrazolones, those with a history of severe blood dyscrasias, and patients for whom safer alternatives are available. Consultation with a healthcare professional is essential before initiating therapy.